LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

Tamoxifen resistance is a major problem in the treatment of ERa positive breast cancer. Here, the authors show that LEM4 confers tamoxifen resistance by activating the cyclin D-CDK4/6-Rb axis and ERa signaling in endocrine-resistant breast cancer.

Saved in:
Bibliographic Details
Main Authors: Ang Gao, Tonghua Sun, Gui Ma, Jiangran Cao, Qingxia Hu, Ling Chen, Yanxin Wang, Qianying Wang, Jiafu Sun, Rui Wu, Qiao Wu, Jiaxi Zhou, Lin Liu, Junjie Hu, Jin-Tang Dong, Zhengmao Zhu
Format: article
Language:EN
Published: Nature Portfolio 2018
Subjects:
Science
Q
Online Access:https://doaj.org/article/7ff9424b6d604decaed08aa4fac77058
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/7ff9424b6d604decaed08aa4fac77058

Similar Items